Peter Emanuel, MD
Hematology & Oncology · Little Rock, ARNPI 1205844594
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (35.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Bristol Myers Squibb at 56.9% of the total. Reporting peaked in 2019 at $25,209 and has fallen 85.1% since, to $3,751 in 2025. Among hematology & oncology clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,080 payments — averaging $48.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$30K
- Janssen Scientific Affairs, LLC$3K
- AstraZeneca$3K
- Novartis$1K
- Merck$1K
- Adaptive Biotechnologies Corporation$1K
- plus $13K from 54 others
What the payments were for
- Consulting fees$11,31821%
- Speaking & faculty fees$18,52535%
- Travel & lodging$3,8427%
- Food & beverage$18,41935%
- Education$6661%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,770 in reported general payments places this provider in the 90th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 40 | $483,740 |
| TasignaNilotinib Hcl | 13 | $243,841 |
| CalquenceAcalabrutinib Maleate | 12 | $187,452 |
| EliquisApixaban | 58 | $44,046 |
| GranixTbo-Filgrastim | 13 | $38,925 |
| XareltoRivaroxaban | 14 | $7,938 |
| Hydroxyurea | 36 | $913 |
| Anastrozole | 36 | $414 |
| Potassium Chloride | 20 | $212 |
| Warfarin Sodium | 11 | $166 |
| Prednisone | 25 | $66 |
| Folic Acid | 13 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $451 | $483,74040 claims |
| NovartisTasigna | $1,484 | $243,84113 claims |
| AstraZenecaCalquence | $2,642 | $187,45212 claims |
| PfizerEliquis | $839 | $44,04658 claims |
| Johnson & JohnsonXarelto | $972 | $7,93814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 92 hematology & oncology providers in Arkansas.
Other hematology & oncology in Little Rock
- Frits van RheeLittle Rock$218K
- Appalanaidu SasapuLittle Rock$63K
- Brad BaltzLittle Rock$25K
- Carolina SchinkeLittle Rock$23K
- Pooja MotwaniLittle Rock$21K
- Naveen YarlagaddaLittle Rock$18K
- Joseph BeckLittle Rock$16K
- Konstantinos ArnaoutakisLittle Rock$12K
- Abhijit GodboleLittle Rock$11K
- Maurizio ZangariLittle Rock$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.